

News Release

Lonza Introduces the New CytoSMART™ 2 System for Live Cell Imaging

Cologne (DE) / Basel (CH), 19 September 2017 – Lonza has today introduced the CytoSMART™ 2 System, an updated version of Lonza's popular CytoSMART™ System for live cell imaging. The CytoSMART™ 2 Device features an advanced optical system and more powerful camera unit, which enables researchers to capture higher-resolution images of their cell cultures. Images taken can be digitally enlarged two-fold to display more cellular detail for enhanced monitoring of cell cultures, migration assays and differentiation experiments.

Lonza's CytoSMART™ 2 System is easy to set up and can take time-lapse recordings without having to remove cultures from the incubator. Since fluctuations in the surrounding environment can affect cellular behavior, capturing images from inside the incubator with the CytoSMART™ 2 Device allows the cells to be exposed to constant conditions throughout the duration of an experiment.

Images taken with the CytoSMART™ 2 System are transmitted to the CytoSMART™ Connect Cloud. This allows researchers to view their cells and download images from the CytoSMART™ Connect Cloud Project Page on a computer, tablet or smartphone at any time and from any location. The system's cell-confluency monitoring function prevents the need to determine confluency by eye – a process that is highly user dependent – ensuring standardization across cultures. In addition, Lonza's CytoSMART™ 2 Device allows scientists to create automatic email alerts to notify them when cultures have reached a desired confluency without having to step into the laboratory.

Data transfer from the CytoSMART™ 2 System to the cloud via WiFi or LAN transmission and its ability to operate offline both allow for flexible image recording and storage to seamlessly integrate with different network set-ups.

“Due to the success of our first CytoSMART™ System, we wanted to develop an updated version with some valuable new features to further assist researchers with their live cell imaging,” said Claudia Schwartz, Product Manager, Lonza. “Scientists already using our CytoSMART™ System can upgrade to the new model to capture higher-resolution images of key cellular processes, including migration, invasion and differentiation. This model will enhance our understanding of diseases like cancer and rheumatoid arthritis. Researchers will also be able to monitor the generation of induced pluripotent stem cells.”

For more information about the CytoSMART™ 2 System, visit: <http://www.lonza.com/cytosmart>

About Lonza

Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Cologne GmbH
Manager Marketing Communications
Petra Haberkamm
Tel +49 221 991990
petra.haberkamm@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.